Oregon Public Employees Retirement Fund lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,797 shares of the biopharmaceutical company’s stock after purchasing an additional 84 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Regeneron Pharmaceuticals were worth $15,518,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $506,839,000. Alliancebernstein L.P. lifted its stake in Regeneron Pharmaceuticals by 13.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,763,344 shares of the biopharmaceutical company’s stock valued at $851,889,000 after acquiring an additional 208,936 shares in the last quarter. Morgan Stanley raised its stake in shares of Regeneron Pharmaceuticals by 56.1% during the 4th quarter. Morgan Stanley now owns 547,337 shares of the biopharmaceutical company’s stock worth $264,425,000 after purchasing an additional 196,601 shares during the period. Assenagon Asset Management S.A. purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $75,487,000. Finally, Brandywine Global Investment Management LLC raised its position in shares of Regeneron Pharmaceuticals by 673.8% in the fourth quarter. Brandywine Global Investment Management LLC now owns 123,966 shares of the biopharmaceutical company’s stock valued at $59,889,000 after purchasing an additional 107,945 shares during the period. 85.00% of the stock is owned by institutional investors.
REGN has been the topic of several recent research reports. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their target price on shares of Regeneron Pharmaceuticals from $575.00 to $584.00 and gave the company a “buy” rating in a report on Thursday, January 14th. FIX raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and cut their price target for the company from $635.00 to $575.00 in a report on Friday, January 8th. Cantor Fitzgerald cut their price objective on Regeneron Pharmaceuticals from $696.00 to $656.00 and set an “overweight” rating for the company in a research note on Tuesday, February 16th. Robert W. Baird restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 13th. Finally, BMO Capital Markets upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a research report on Monday, January 25th. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $644.17.
REGN opened at $490.43 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $441.00 and a one year high of $664.64. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.12 and a current ratio of 3.89. The stock has a market cap of $52.54 billion, a price-to-earnings ratio of 17.93, a P/E/G ratio of 0.82 and a beta of 0.30. The stock’s 50 day moving average price is $476.97 and its 200-day moving average price is $509.39.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, February 4th. The biopharmaceutical company reported $9.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $7.11 by $2.42. Regeneron Pharmaceuticals had a return on equity of 28.97% and a net margin of 38.28%. The company had revenue of $2.42 billion for the quarter, compared to the consensus estimate of $2.40 billion. During the same quarter in the prior year, the company posted $7.50 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 11.7% on a year-over-year basis. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 27.23 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Recommended Story: Why investors pay attention to retained earnings
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.